These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

900 related items for PubMed ID: 23386065

  • 1. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 2. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 3. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Apr 15; 20(8):2029-34. PubMed ID: 24573551
    [Abstract] [Full Text] [Related]

  • 4. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May 15; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 5. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A, Wood K, Salgia R.
    Expert Opin Drug Saf; 2015 Mar 15; 14(3):485-93. PubMed ID: 25659177
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
    Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A.
    Drugs Today (Barc); 2012 Apr 15; 48(4):271-82. PubMed ID: 22536569
    [Abstract] [Full Text] [Related]

  • 8. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011 Apr 15; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 9. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L.
    Expert Opin Investig Drugs; 2012 Jul 15; 21(7):985-94. PubMed ID: 22612599
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.
    Qian H, Gao F, Wang H, Ma F.
    BMC Cancer; 2014 Sep 19; 14():683. PubMed ID: 25239305
    [Abstract] [Full Text] [Related]

  • 11. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 12. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM, Bepler G.
    Future Oncol; 2011 Aug 01; 7(8):947-53. PubMed ID: 21823889
    [Abstract] [Full Text] [Related]

  • 13. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH.
    Expert Rev Anticancer Ther; 2012 Feb 01; 12(2):151-62. PubMed ID: 22316363
    [Abstract] [Full Text] [Related]

  • 14. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 01; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 15. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM, Rudin CM.
    Expert Opin Pharmacother; 2012 Jun 01; 13(8):1195-201. PubMed ID: 22594847
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
    Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R.
    Oncologist; 2014 Oct 01; 19(10):e5-11. PubMed ID: 25170012
    [Abstract] [Full Text] [Related]

  • 18. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R.
    Expert Opin Drug Discov; 2013 Sep 01; 8(9):1165-79. PubMed ID: 23805942
    [Abstract] [Full Text] [Related]

  • 19. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep 01; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

  • 20. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 01; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.